培哚普利对慢性心力衰竭患者血浆偶联因子6表达变化的影响  

Effect of perindopril on expression of plasma coupling factor 6 in patients with chronic heart failure

作　　者：章海燕[1] 龙明智[1] 

机构地区：[1]南京医科大学第二附属医院心内科,南京210011

出　　处：《实用药物与临床》2014年第10期1255-1257,共3页Practical Pharmacy and Clinical Remedies

基　　金：南京市医学科技发展青年科技人才启动项目(QYK09155)

摘　　要：目的观察慢性心力衰竭患者入院前后血浆偶联因子6(CF6)水平的动态变化。方法随机入选60例慢性心衰患者,根据心功能分级情况,按照指南规定提供标准化治疗,于入院即刻及入院后第5、10、14天分别测定血浆CF6及前列环素(PGI2)变化水平,观察慢性心衰患者经过治疗后,其CF6及PGI2的变化情况。结果慢性心力衰竭患者组入院时血浆CF6水平明显高于正常对照组,而PGI2水平明显降低,两组比较差异有统计学意义(P<0.01)。随着入院后治疗的进行,心衰各组CF6水平较入院时下降,且在不同时间点出现显著性差异,PGI2逐渐上升,且随着培哚普利剂量的增加,其下降或上升趋势更为明显。结论 CF6参与了慢性心力衰竭的病理生理过程,培哚普利通过纠正心衰患者血液动力学、改善内皮细胞功能等途径抑制CF6释放,提高PGI2,达到治疗心衰、改善患者预后的目的。Objective To observe the dynamical expression of the plasma coupling factor 6（CF6）levels in patients with chronic heart failure（CHF）before and after admission and effects of perindopril on the factors. Methods All 60 patients with CHF were selected at random. The standardized treatment was provided according to the regulations of the guideline based on the grade of cardiac function. The plasma levels of CF6 and prostacyclin（PGI2） were determined in all patients on immediate admission and 5,10,14 days after admission. The dynamic change of the plasma factors were compared before and after the treatment. Results The plasma CF6 levels immediately after admission in patients with CHF were significantly higher and the PGI2 levels were obviously lower than those of control group（ P〈0. 05）. The CF6 levels gradually decreased along with the increase of the PGI2 levels after the treatment and there was significant difference at different time points. The trends became obvious with the increased dosage of perindopril. Conclusion CF6 might involve in the pathophysiologic course of CHF. Perindopril can inhibit the release of plasma CF6 and elevate the PGI2 levels thus treat patients with CHF and improve prognosis by means of correcting the hemodynamics and improving endothelial cell function in patients with heart failure.

关 键 词：偶联因子6 慢性心力衰竭 培哚普利 

分 类 号：R541.6[医药卫生—心血管疾病]